AzTrials
AzTrials

Brain IschemiaCSINCT06270927

A Feasibility Study for Randomization of Code Stroke Imaging Strategies

An observational study of Brain Ischemia, run by University of Texas at Austin at 1 site in United States.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

The purpose of this study is to test feasibility of a comparative effectiveness framework for acute stroke imaging using prospective electronic health data. This is a prospective, cohort feasibility study of patients presenting to the Emergency Department with suspected acute ischemic stroke. Read more about this study

Who is it for?
Ages 18 to 120 yearsHealthy volunteers can take part
Conditions the study is for
Brain Ischemia
What is being tested?
MRI and CT
How many people
600 participants
Where
1 siteUnited States
Study dates
23 Oct 2023to 31 May 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 120 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Patients presenting as Code Stroke to Emergency Department at one of four network stroke centers

Who may be able to join

  • Age ≥ 18 years
  • Time last known well to presentation ≤ 24 hours
  • Code-stroke (suspected treatable ischemic stroke) called prior to or upon arrival to Emergency Department
  • Presenting to Emergency Department for first time during study period

Who cannot join

  • Transfer patients
  • Contraindication for brain perfusion scan
  • Prior inclusion in study

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Ascension Seton

    Austin, Texas, 78712

Other trials in United States

About this study

Official title: • Code Stroke Imaging (CSI): MRI Or CT As First Scan For Acute Stroke Evaluation And Management

The purpose of this study is to test feasibility of a comparative effectiveness framework for acute stroke imaging using prospective electronic health data. This is a prospective, cohort feasibility study of patients presenting to the Emergency Department with suspected acute ischemic stroke. The clinical stroke team will not be blinded to the imaging modality given the nature and purpose of the interventions/imaging. Knowledge of the imaging modality used and the knowledge gained from the resulting data will need to be considered for treatment decisions. Blinding will be maintained for data abstraction and analyses. Analysis will be on an "intent-to-scan" basis and all qualifying patients will be included in their assigned cohort.

Read the detailed description

The purpose of this study is to test feasibility of a comparative effectiveness framework for acute stroke imaging using prospective electronic health data. This is a prospective, cohort feasibility study of patients presenting to the Emergency Department with suspected acute ischemic stroke. The clinical stroke team will not be blinded to the imaging modality given the nature and purpose of the interventions/imaging. Knowledge of the imaging modality used and the knowledge gained from the resulting data will need to be considered for treatment decisions. Blinding will be maintained for data abstraction and analyses. Analysis will be on an "intent-to-scan" basis and all qualifying patients will be included in their assigned cohort.

All patients will receive standard-of-care therapy and management based on AHA/ASA clinical practice guidelines. For patients with emergent large vessel occlusions, this will include adjuvant endovascular therapy if criteria, as stipulated in the guideline, are met. Although this is referred to as a prospective study, no data collection will occur until after standard of care procedures.

Population: "Code-Stroke" (potentially-treatable) patients, defined as patients presenting with clinical syndrome suggestive of stroke within 24-hours of time last known well will be included.

Setting: four certified stroke centers (Ascension Seton Williamson, Ascension Seton Medical Center, Ascension Seton Hayes, and Dell Seton Medical Center)

Rationale: There is current equipoise in selection of first scan modality for code stroke. The time-dependent efficacy of treatment with thrombolytics increases diagnostic burden on the stroke team, particularly less experienced providers. In efforts to minimize door to needle time (DTN), stroke mimics may be inadvertently treated with thrombolytics, particularly when insensitive diagnostics are used. The investigators plan to examine feasibility of comparing CT-first versus MR-first strategies to guide the development of a future large multicenter comparison.

Methodology: The first-scan imaging modality will be assigned using two different schemes, a) clustered by hospital site and b) per-patient. Each scheme will be developed by a UT statistician or study team member, please see details in Randomization Schemes section below.

All practices will follow standard of care methods, no investigational procedures or interventions will occur as part of this study. A stroke alert is called prior to the arrival of the patient to the Emergency Department (ED). With this, patient information is communicated by the Emergency Medical Services team to the care team at the destination hospital to determine if the patient is potentially treatable (Code-Stroke).

Patient enrollment. Once a Code-Stroke is called, this will establish the patient eligible for the study and they will be enrolled. All stroke alerts are communicated via text message to the care team. The charge nurse leads a huddle prior to the arrival of each Code-Stroke patient. At the time the Code-Stroke is called, the first-scan imaging modality will be assigned and the patient will be enrolled.

Communication of assigned first-scan modality. The assigned first-scan imaging modality will be communicated via the ED charge nurse to all members of the care team including attending physicians, residents, and nursing staff. The mode of communication will be site-specific and include any of the following: verbal communication at initial pre-arrival stroke-alert huddle, sign posted at charge nurse desk that can be flipped to either "MRI" or "CT" typed in large letters, sign at scanners, sign at ED entrance. This will ensure the entire care team is aware and reminded of the first-scan modality assigned. This procedure was developed in close collaboration with Emergency Medicine attendings along with ED Medical and Nursing Directors at each participating hospital site.

Randomization Schemes: The prospective study includes two phases in which different randomization schemes will be evaluated for feasibility. Randomization schemes will be established a priori by the study Biostatistician. The Phases are as follows:

  1. Multi-Center Hospital-Level Cluster Randomization - (Phase A) During the cluster randomized study period, everyone at the hospital is getting the same standard of care (diagnostic), the patient is not being randomized. The imaging modality used as first-scan for code stroke will be the hospital strategy and not determined on a per-patient basis. A randomization period equal to one-week in which the imaging modality will be either CT or MRI for all patients at the site. This will be implemented for a study length of 12 weeks. Within this 12-week period, 4-week blocks will be used to ensure balance in the assignment to either CT or MRI. Randomization schemes will be independent across the four participating sites and start will be staggered by one week.

This cluster randomization is designed to test feasibility of a comparative effectiveness framework using prospective electronic health data. This study design challenges the traditional research ethics paradigm. Rather than testing experimental, unproven interventions, the research question asks how interventions that are widely used compare, and deploys these interventions in ways consistent with good clinical practice at the hospital level.

  1. Per-Patient Randomization - (Phase B) During the per-patient randomization, the first-scan imaging modality will be assigned to each eligible patient. A block size of 10 patients will be implemented to ensure balance in assignment to CT and MRI. The accrual of patients to meet this 10-patient block will be specific to each hospital site. Enrollment will be 5 weeks in duration. Randomization will be independent across sites. The assigned imaging modality will be communicated prior to each Code-Stroke and posted at the charge nurse station in the ED. With this, the entire stroke care team will know the assignment for the next Code-Stroke patient prior to their arrival.
Conditions
Brain Ischemia
Being tested
MRI, CT
Keywords
Stroke, Neuroimaging
Medical subject headings
Brain Ischemia, Stroke

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MRIDiagnostic test

    Also called magnetic resonance imaging

    neuroimaging using MRI scanner

  • CTDiagnostic test

    Also called computed tomography

    neuroimaging using CT scanner

Study groups in NCT06270927
Study groupRoleWhat they receive
MRIpatients assigned to MRI
Receives: Diagnostic Test: MRI; Diagnostic Test: CT
CTpatients assigned to CT
Receives: Diagnostic Test: MRI; Diagnostic Test: CT

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. compliance

    adherence to assigned first-scan imaging modality quantified as number of cross-overs (i.e., MRI scheduled but CT performed) relative to the sample size.

    Measured: Two phases will be included. Phase A: 12 weeks of cluster randomization with the initiation of each site staggered by 1 week, for a total of 15 weeks Phase B: 5 weeks of per-patient randomization Total time for enrollment: 20 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Feb 2024
  2. Study start23 Oct 2023
  3. Primary completion30 Dec 2025
  4. Study completion31 May 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
600 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06270927
Sponsor's protocol ID
00003830
Acronym
CSI
Status last verified
Apr 2026
First submitted
12 Jan 2024
Last updated
1 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Brain Ischemia, run by University of Texas at Austin at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 1 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

compliance (time frame: Two phases will be included. Phase A: 12 weeks of cluster randomization with the initiation of each site staggered by 1 week, for a total of 15 weeks Phase B: 5 weeks of per-patient randomization Total time for enrollment: 20 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 May 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in